Cargando…

The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation

Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Peng, Xiong, Dan-Dan, Dang, Yi-Wu, Yang, Hong, He, Yun, Wen, Dong-Yue, Qin, Xin-Gan, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696199/
https://www.ncbi.nlm.nih.gov/pubmed/29190933
http://dx.doi.org/10.18632/oncotarget.21438
_version_ 1783280398562754560
author Lin, Peng
Xiong, Dan-Dan
Dang, Yi-Wu
Yang, Hong
He, Yun
Wen, Dong-Yue
Qin, Xin-Gan
Chen, Gang
author_facet Lin, Peng
Xiong, Dan-Dan
Dang, Yi-Wu
Yang, Hong
He, Yun
Wen, Dong-Yue
Qin, Xin-Gan
Chen, Gang
author_sort Lin, Peng
collection PubMed
description Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investigation. A total of 25 datasets and 12 publications were finally incorporated. Additional immunohistochemistry was conducted to validate the expression pattern of PLK1 in GC. The pooled standard mean deviation (SMD) indicated that PLK1 mRNA was up-regulated in GC (SMD=1.21, 95% CI: 0.65-1.77, P< 0.001). Similarly, the pooled odds ratio (OR) revealed that PLK1 protein was overexpressed in GC compared with normal gastric tissue (OR=12.12, 95% CI: 5.41-27.16, P<0.001). The area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve was 0.86. Furthermore, our results demonstrated that GC patients with PLK1 overexpression were significantly associated with unfavorable overall survival (HR =1.54, 95% CI: 1.30–1.83, P<0.001), lymph node metastasis (OR = 1.78, 95% CI: 1.13–2.80, P=0.013) and advanced TNM stage (OR=1.48, 95% CI: 1.02-2.15, P=0.038). Altogether, 100 similar genes were identified by Gene Expression Profiling Interactive Analysis (GEPIA) and further with gene-set enrichment analysis. These genes were related to gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relevant to the cell cycle. Gene set enrichment analysis (GSEA) indicated that PLK1 is associated with various cancer-related pathways. Collectively, this study suggests that PLK1 overexpression could play vital roles in the carcinogenesis and deterioration of GC via regulating tumor-related pathways.
format Online
Article
Text
id pubmed-5696199
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56961992017-11-29 The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation Lin, Peng Xiong, Dan-Dan Dang, Yi-Wu Yang, Hong He, Yun Wen, Dong-Yue Qin, Xin-Gan Chen, Gang Oncotarget Research Paper Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investigation. A total of 25 datasets and 12 publications were finally incorporated. Additional immunohistochemistry was conducted to validate the expression pattern of PLK1 in GC. The pooled standard mean deviation (SMD) indicated that PLK1 mRNA was up-regulated in GC (SMD=1.21, 95% CI: 0.65-1.77, P< 0.001). Similarly, the pooled odds ratio (OR) revealed that PLK1 protein was overexpressed in GC compared with normal gastric tissue (OR=12.12, 95% CI: 5.41-27.16, P<0.001). The area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve was 0.86. Furthermore, our results demonstrated that GC patients with PLK1 overexpression were significantly associated with unfavorable overall survival (HR =1.54, 95% CI: 1.30–1.83, P<0.001), lymph node metastasis (OR = 1.78, 95% CI: 1.13–2.80, P=0.013) and advanced TNM stage (OR=1.48, 95% CI: 1.02-2.15, P=0.038). Altogether, 100 similar genes were identified by Gene Expression Profiling Interactive Analysis (GEPIA) and further with gene-set enrichment analysis. These genes were related to gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relevant to the cell cycle. Gene set enrichment analysis (GSEA) indicated that PLK1 is associated with various cancer-related pathways. Collectively, this study suggests that PLK1 overexpression could play vital roles in the carcinogenesis and deterioration of GC via regulating tumor-related pathways. Impact Journals LLC 2017-09-30 /pmc/articles/PMC5696199/ /pubmed/29190933 http://dx.doi.org/10.18632/oncotarget.21438 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Lin, Peng
Xiong, Dan-Dan
Dang, Yi-Wu
Yang, Hong
He, Yun
Wen, Dong-Yue
Qin, Xin-Gan
Chen, Gang
The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title_full The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title_fullStr The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title_full_unstemmed The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title_short The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
title_sort anticipating value of plk1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696199/
https://www.ncbi.nlm.nih.gov/pubmed/29190933
http://dx.doi.org/10.18632/oncotarget.21438
work_keys_str_mv AT linpeng theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT xiongdandan theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT dangyiwu theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT yanghong theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT heyun theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT wendongyue theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT qinxingan theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT chengang theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT linpeng anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT xiongdandan anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT dangyiwu anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT yanghong anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT heyun anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT wendongyue anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT qinxingan anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation
AT chengang anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation